HK1200274A1 - Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate - Google Patents
Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetateInfo
- Publication number
- HK1200274A1 HK1200274A1 HK15100236.7A HK15100236A HK1200274A1 HK 1200274 A1 HK1200274 A1 HK 1200274A1 HK 15100236 A HK15100236 A HK 15100236A HK 1200274 A1 HK1200274 A1 HK 1200274A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- single nucleotide
- nucleotide polymorphisms
- clinical response
- glatiramer acetate
- predict clinical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161545282P | 2011-10-10 | 2011-10-10 | |
US201261636560P | 2012-04-20 | 2012-04-20 | |
PCT/US2012/059352 WO2013055683A1 (en) | 2011-10-10 | 2012-10-09 | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1200274A1 true HK1200274A1 (en) | 2015-08-07 |
Family
ID=48082342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15100236.7A HK1200274A1 (en) | 2011-10-10 | 2015-01-09 | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
Country Status (17)
Country | Link |
---|---|
US (2) | US8815511B2 (es) |
EP (1) | EP2765857A4 (es) |
JP (1) | JP2014530819A (es) |
KR (1) | KR20140101730A (es) |
CN (1) | CN103957705A (es) |
AR (1) | AR088294A1 (es) |
AU (1) | AU2012323345A1 (es) |
BR (1) | BR112014008752A2 (es) |
CA (1) | CA2851510A1 (es) |
EA (1) | EA201490749A1 (es) |
HK (1) | HK1200274A1 (es) |
IL (1) | IL231723A0 (es) |
MX (1) | MX2014004309A (es) |
TW (1) | TW201326399A (es) |
UY (1) | UY34380A (es) |
WO (1) | WO2013055683A1 (es) |
ZA (1) | ZA201403049B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2612001T4 (es) | 2009-08-20 | 2018-02-07 | Yeda Research & Development Company, Ltd. | Terapia de baja frecuencia con acetato de glatirámero |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
NZ609938A (en) | 2010-10-11 | 2015-11-27 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
JP2014530819A (ja) | 2011-10-10 | 2014-11-20 | テバ ファーマシューティカル インダストリーズ リミティド | 酢酸グラチラマーに対する臨床的応答性を予測するために有用な一塩基多形 |
EP2906719A4 (en) | 2012-10-10 | 2016-11-09 | Teva Pharma | PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
US20160312284A1 (en) * | 2015-04-21 | 2016-10-27 | Teva Pharmaceutical Industries, Ltd. | Select single nucleotide polymorphisms predictive of response to glatiramer acetate |
CA3050086A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
US11396825B2 (en) * | 2017-08-14 | 2022-07-26 | General Electric Company | Turbine diagnostic feature selection system |
EP3874455A4 (en) * | 2018-11-01 | 2022-08-03 | I2Dx, Inc. | INTELLIGENT SYSTEM AND METHOD FOR THERAPY TARGET RECOGNITION |
AU2020285475A1 (en) * | 2019-05-30 | 2021-12-23 | PolygenRx Pty Ltd | A method of treatment or prophylaxis |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
JP2003521448A (ja) | 1998-07-23 | 2003-07-15 | ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 合成ペプチドおよび自己免疫疾患治療のための使用方法 |
EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES |
ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
DK2090583T3 (da) | 1998-09-25 | 2011-09-12 | Yeda Res & Dev | Copolymer 1-relaterede polypeptider til anvendelse som molekylvægtsmarkører og til terapeutisk anvendelse |
US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
WO2000020010A1 (en) | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
EP1128839A4 (en) | 1998-11-12 | 2002-10-09 | Yeda Res & Dev | PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD |
DE60112718T2 (de) | 2000-01-20 | 2006-06-29 | Yeda Research And Development Co., Ltd. | Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie |
EP1261361B1 (en) | 2000-02-18 | 2006-06-14 | Yeda Research And Development Company, Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 (glatiramer acetate) |
US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
HUP0302333A3 (en) | 2000-06-05 | 2005-07-28 | Teva Pharma | The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders |
US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
ATE314860T1 (de) | 2000-06-07 | 2006-02-15 | Yeda Res & Dev | Verwendung des copolymer-1 peptids sowie von damit verwandten peptiden und polypeptiden und von damit behandelten t-zellen zur neuroprotektion vor glutamattoxizitaet |
WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
ES2349033T3 (es) | 2001-12-04 | 2010-12-22 | Teva Pharmaceutical Industries, Ltd. | Procedimientos para la medida de la actividad del acetato de glatiramer. |
DK1429800T3 (da) | 2001-12-06 | 2009-04-27 | Yeda Res & Dev | Vaccine og anvendelse deraf til behandling af amyotrofisk lateral sklerose |
US7507531B2 (en) | 2002-10-17 | 2009-03-24 | Decode Genetics Chf. | Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction |
US20060019269A1 (en) | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
US20080293750A1 (en) | 2002-10-17 | 2008-11-27 | Anna Helgadottir | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment |
EP1565486A2 (en) | 2002-11-13 | 2005-08-24 | Apotex Pharmachem Inc. | Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine |
US20070248569A1 (en) | 2003-01-07 | 2007-10-25 | Michal Eisenbach-Schwartz | Eye-Drop Vaccine Containing Copolymer 1 for Therapeutic Immunization |
US8008258B2 (en) | 2003-01-21 | 2011-08-30 | Yeda Research And Development Co. Ltd. | Cop 1 for treatment of inflammatory bowel diseases |
CA2518079A1 (en) | 2003-03-04 | 2004-10-28 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
PT1638589E (pt) | 2003-05-14 | 2014-06-12 | Teva Pharma | Terapia combinada com acetato de glatirâmero e mitoxantrona para o tratamento da esclerose múltipla |
US20050064483A1 (en) * | 2003-08-28 | 2005-03-24 | Baylor College Of Medicine | Gene expression profiling technology for treatment evaluation of multiple sclerosis |
CN1886506B (zh) | 2003-09-29 | 2012-05-30 | 中外制药株式会社 | 在nk细胞中表达的蛋白质 |
WO2005041933A1 (en) | 2003-10-31 | 2005-05-12 | Teva Pharmaceutical Industries, Ltd. | Nanoparticles for drug delivery |
JP5456235B2 (ja) | 2003-11-12 | 2014-03-26 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経変性疾患を治療するためのワクチン及び方法 |
US20100216863A1 (en) | 2004-01-30 | 2010-08-26 | Decode Genetics Ehf. | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment |
JP2007538003A (ja) | 2004-01-30 | 2007-12-27 | デコード ジェネティクス イーエッチエフ. | 心筋梗塞、脳卒中および末梢動脈閉塞疾患に対する感受性遺伝子、治療の方法 |
US20050266432A1 (en) * | 2004-02-26 | 2005-12-01 | Illumina, Inc. | Haplotype markers for diagnosing susceptibility to immunological conditions |
AU2005218625A1 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
US20050266410A1 (en) | 2004-05-19 | 2005-12-01 | Emily Walsh | Methods of Human Leukocyte Antigen typing by neighboring single nucleotide polymorphism haplotypes |
CA2571035A1 (en) * | 2004-06-25 | 2006-01-12 | Id Biomedical Corporation Of Quebec | Compositions and methods for treating neurological disorders |
EP1796710A4 (en) | 2004-09-02 | 2010-05-26 | Teva Pharma | THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS |
ATE536363T1 (de) | 2004-09-09 | 2011-12-15 | Teva Pharma | Verfahren zur herstellung von mischungen von trifluoroacetyl-glatirameracetat bei verwendung von hydrobromsäure |
SI1797109T1 (sl) | 2004-09-09 | 2016-07-29 | Yeda Research And Development Co., Ltd. | Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe |
WO2006050122A1 (en) | 2004-10-29 | 2006-05-11 | Sandoz Ag | Processes for preparing glatiramer |
AU2006211510B8 (en) | 2005-02-02 | 2011-04-21 | Teva Pharmaceutical Industries, Ltd. | Process for producing polypeptide mixtures using hydrogenolysis |
PL1848415T3 (pl) | 2005-02-17 | 2013-10-31 | Teva Pharma | Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego |
US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
WO2006116602A2 (en) * | 2005-04-25 | 2006-11-02 | Yeda Research And Development Company | Markers associated with the therapeutic efficacy of glatiramer acetate |
WO2007030573A2 (en) | 2005-09-09 | 2007-03-15 | Yeda Research And Development Co. Ltd. | Polypeptides useful for molecular weight determinations |
WO2007081975A2 (en) | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
US20080118553A1 (en) | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
SI2046817T1 (sl) | 2006-07-05 | 2010-04-30 | Momenta Pharmaceuticals Inc | Izboljšani postopek za pripravo kopolimera-1 |
US20080131887A1 (en) * | 2006-11-30 | 2008-06-05 | Stephan Dietrich A | Genetic Analysis Systems and Methods |
US7795033B2 (en) | 2007-03-19 | 2010-09-14 | The United States Of America As Represented By The Department Of Health And Human Services | Methods to predict the outcome of treatment with antidepressant medication |
AU2008330093A1 (en) | 2007-11-28 | 2009-06-04 | Yeda Research And Development Co., Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
US20090177487A1 (en) | 2008-01-07 | 2009-07-09 | Tera Eerkes | Methods for Assessing Genetic Compatibility |
CA2727795A1 (en) | 2008-06-13 | 2009-12-17 | Prognomix, Inc. | Genetic component of complications in type 2 diabetes |
AU2009266947A1 (en) | 2008-07-04 | 2010-01-07 | Axial Biotech, Inc | Genetic markers associated with degenerative disc disease and uses thereof |
EP2406396A2 (en) * | 2009-03-12 | 2012-01-18 | Brainco Biopharma, S.L. | A genotyping tool for improving the prognostic and clinical management of ms patients |
US20120073585A1 (en) | 2009-04-08 | 2012-03-29 | Cedars-Sinai Medical Center | Methods of predicting complication and surgery in crohn's disease |
US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
PL2275086T3 (pl) | 2009-07-15 | 2012-09-28 | Teva Pharma | Formulacja octanu glatirameru o zredukowanej objętości oraz sposoby podawania |
ES2612001T4 (es) | 2009-08-20 | 2018-02-07 | Yeda Research & Development Company, Ltd. | Terapia de baja frecuencia con acetato de glatirámero |
WO2011043823A2 (en) | 2009-10-09 | 2011-04-14 | Georgetown University | Polypeptides that home to atherosclerotic plaque |
US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
NZ609938A (en) | 2010-10-11 | 2015-11-27 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
JP2014530819A (ja) | 2011-10-10 | 2014-11-20 | テバ ファーマシューティカル インダストリーズ リミティド | 酢酸グラチラマーに対する臨床的応答性を予測するために有用な一塩基多形 |
EP2906719A4 (en) | 2012-10-10 | 2016-11-09 | Teva Pharma | PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE |
AU2013361057A1 (en) | 2012-12-21 | 2015-07-30 | Teva Pharmaceutical Industries Ltd. | Oral transmucosal delivery of glatiramer acetate |
US20160193276A1 (en) | 2012-12-21 | 2016-07-07 | Teva Pharmaceutical Industries, Ltd. | Transmucosal delivery of glatiramer acetate |
KR20150111945A (ko) | 2013-01-04 | 2015-10-06 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트 관련 완제의 특성조사 |
JP2016512552A (ja) | 2013-03-12 | 2016-04-28 | テバ ファーマシューティカル インダストリーズ リミティド | リツキシマブ導入療法とその後の酢酸グラチラマー療法 |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
-
2012
- 2012-10-09 JP JP2014535787A patent/JP2014530819A/ja not_active Withdrawn
- 2012-10-09 US US13/648,135 patent/US8815511B2/en not_active Expired - Fee Related
- 2012-10-09 EP EP12840243.5A patent/EP2765857A4/en not_active Withdrawn
- 2012-10-09 KR KR1020147012550A patent/KR20140101730A/ko not_active Application Discontinuation
- 2012-10-09 AU AU2012323345A patent/AU2012323345A1/en not_active Abandoned
- 2012-10-09 BR BR112014008752A patent/BR112014008752A2/pt not_active IP Right Cessation
- 2012-10-09 MX MX2014004309A patent/MX2014004309A/es unknown
- 2012-10-09 CA CA2851510A patent/CA2851510A1/en not_active Abandoned
- 2012-10-09 EA EA201490749A patent/EA201490749A1/ru unknown
- 2012-10-09 TW TW101137349A patent/TW201326399A/zh unknown
- 2012-10-09 WO PCT/US2012/059352 patent/WO2013055683A1/en active Application Filing
- 2012-10-09 CN CN201280058097.0A patent/CN103957705A/zh active Pending
- 2012-10-10 AR ARP120103778A patent/AR088294A1/es unknown
- 2012-10-10 UY UY0001034380A patent/UY34380A/es not_active Application Discontinuation
-
2014
- 2014-03-26 IL IL231723A patent/IL231723A0/en unknown
- 2014-04-25 ZA ZA2014/03049A patent/ZA201403049B/en unknown
- 2014-08-25 US US14/467,954 patent/US9499868B2/en not_active Expired - Fee Related
-
2015
- 2015-01-09 HK HK15100236.7A patent/HK1200274A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN103957705A (zh) | 2014-07-30 |
TW201326399A (zh) | 2013-07-01 |
CA2851510A1 (en) | 2013-04-18 |
AR088294A1 (es) | 2014-05-21 |
US8815511B2 (en) | 2014-08-26 |
US20130123189A1 (en) | 2013-05-16 |
IL231723A0 (en) | 2014-05-28 |
EP2765857A4 (en) | 2015-12-09 |
AU2012323345A1 (en) | 2014-05-22 |
EA201490749A1 (ru) | 2014-09-30 |
JP2014530819A (ja) | 2014-11-20 |
US9499868B2 (en) | 2016-11-22 |
ZA201403049B (en) | 2015-09-30 |
KR20140101730A (ko) | 2014-08-20 |
WO2013055683A1 (en) | 2013-04-18 |
MX2014004309A (es) | 2015-07-06 |
NZ624258A (en) | 2016-09-30 |
US20150045306A1 (en) | 2015-02-12 |
UY34380A (es) | 2013-05-31 |
BR112014008752A2 (pt) | 2017-04-25 |
EP2765857A1 (en) | 2014-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1200274A1 (en) | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate | |
HK1216254A1 (zh) | 取代的核苷酸類似物 | |
IL227853A0 (en) | A test for detecting autoantibodies to anti-tnfα drugs | |
ZA201400678B (en) | Alpha-amylase variants | |
IL221072A0 (en) | Single unit antibody purification | |
SI3623481T1 (sl) | Sestavki za sekvenciranje nukleinske kisline | |
EP2676122A4 (en) | AMPEROMETRIC SENSOR SYSTEM | |
EP2545523A4 (en) | ADAPTABLE RELEVANCE METHODS FOR SOCIAL ACTIVITY FLOWS | |
PT3517956T (pt) | Ensaios de atividade dependente de modificação | |
EP2686822A4 (en) | SUPPORT SYSTEM FOR CLINICAL DECISION MAKING | |
GB201114379D0 (en) | Temperature sensor | |
EP2625290A4 (en) | REAL-TIME PCR DETECTION OF INDIVIDUAL NUCLEOTIDE POLYMORPHISMS | |
GB201118636D0 (en) | Nucleotide sequence | |
HK1213830A1 (zh) | 用於預測醋酸格拉替雷臨床反應的生物標誌物 | |
EP2627669A4 (en) | BIOLOGICAL MARKERS BASED ON CYTOKINE AS BIOLOGICAL MARKERS PREDICTIVE OF CLINICAL RESPONSE TO GLATIRAMÈRE ACETATE | |
EP2773554A4 (en) | TRETLAGER WITH TWO SPEEDS | |
EP2778668A4 (en) | MULTI-REACTION BIOSENSOR | |
EP2798092A4 (en) | nucleic acid hybridization probes | |
GB2489486B (en) | Improvements relating to construction | |
EP2664917A4 (en) | METHOD FOR DETECTION OF MONOBASIC POLYMORPHISM | |
GB2479833B (en) | Modified nucleotides | |
EP2682462A4 (en) | (Nucleic acid) polysaccharide COMPLEX | |
EP2712423A4 (en) | ANALYZES FOR DETECTING ENZYMATIC ACTIVITY | |
EP2594592A4 (en) | COMPLEX (NUCLEIC ACID) -POLYSACCHARIDE | |
HK1187672A1 (zh) | 熱電偶的安裝結構 |